Osteosarcoma (OS) is a bone malignancy of mesenchymal origin predominantly affecting children. Despite the advances achieved in chemotherapy, radiotherapy and surgical ablation of the primary tumor over the past decades, only around 20% patients who develop pulmonary metastases are rendered free of disease. Our lab has established an osteosarcoma mouse model using tumor-initiating cells (TICs) from osteosarcoma biopsies (Cancer Res. 2009 Jul 15; 69(14): . With the animal model, we would like to develop targeted therapeutics for the treatment of osteosarcoma by using recombinant adeno-associated viral vector (AAV) based gene therapy. In collaboration with Dr. Sergei Zolotukhin's lab, we have designed a directed evolution approach from a combinatorial library of genetic variants to isolate novel AAV capsid mutants, which can effi ciently and specifi cally target osteosarcoma TICs. Results after two rounds of in vivo biopanning showed highly enriched AAV capsid variants for OS. As a control, we also applied the same approach to the mouse lung, where OS metastasizes, to differentiate OS specifi c and non-specifi c variants. Then, we performed detailed analysis of resulting OS-variants for their packaging effi ciencies, transduction effi ciencies on several OS TICs and in vivo studies. We found a novel capsid variant, AAV-OSLM-HD4, showed high transgene expression as early as 24 hrs post injection which is more rapid and enhanced than both wild type AAV2 and AAV8 capsids. Importantly, transgene expression was mainly restricted in the tumor and undetectable in the collateral tissues in OS mouse model. Long-term observation of AAV-OSLM-HD4 in naive animals identifi ed limited transgene expression with liver-detargeted and systemic profi le. We believe this approach will allow us to identify novel AAV capsids with elevated and osteosarcoma-specifi c properties for use in clinical studies.
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Bystander Tumor Cell Killing Mediated by Gap Junctions Formed with MSCs Engineered to Express Novel Prodrug-Converting Enzymes
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Mesenchymal stem cells (MSCs) are a versatile cell population with compelling clinical potential in a wide range of applications. Of key relevance to our study, infused MSCs exhibit intrinsic infl ammation region-homing properties in recipients that make them attractive vehicles for payload delivery to tumors. Prodrug-converting enzymes (PCEs) that activate normally non-toxic prodrugs to potent cytotoxic metabolites are excellent candidate payloads for MSCs in such an application. Upon homing to tumors, MSCs expressing PCEs can then deliver activated chemotherapeutic compounds directly and specifi cally to tumor cells through gap-junction-mediated bystander interactions. We carried out the fi rst side-by-side comparisons of tumor cell killing using three PCE systems in MSCs. Archetypal Herpes Simplex Virus-derived thymidine kinase (HSV-tk) was compared with next-generation variants for human thymidylate kinase (tmpKF105Y) and human deoxycytidine kinase (dCK.DM.S74E) that we have previously described. Novel fusion constructs/proteins were generated for this study that combined the ectodomain of the cell surface marker CD19 with the PCE sequences yielding: HSVtk (CD19HSV-tk), tmpKF105Y (CD19tmpK), and dCK.DM.S74E (CD19dCK). Expression of these novel PCE-fusion constructs allows facile quantifi cation of vector titer and transgene expression levels and subsequently promotes homodimerization/prodrug activation. High-titer recombinant lentiviral vectors were generated in our Vector Core Facility at the UHN to facilitate gene transfer into target human MSCs provided by apceth. Stable expression of each of the PCE-fusion cassettes was achieved. Assessments of expression levels of these fusion proteins further allowed us to normalize cytotoxic responses to PCE levels. Formation of MSC-tumor gap junctions were confi rmed by evidence of dye transfer from the human MSCs to the human U87mg glioblastoma cells. In vitro bystander assays using MSCs expressing either CD19HSV-tk or CD19tmpk showed effective induction of apoptosis in bystander U87mg.eGFP glioblastoma cells upon GCV and AZT treatment, respectively, with a dramatically reduced frequency of target cells in cultures. Additional studies are underway to examine dosing and the kinetics of cytotoxic pro-drug conversion and tumor cell killing. Additional tumor cells of differential originations will also be tested in vitro and in vivo. As MSCs can be readily obtained, expanded, and transduced, implementation of this strategy can provide a promising approach to treat refractory cancers.
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The renin-angiotensin system meets the hallmarks of cancer. Angiotensin II type 2 receptor (AT2R) was localized at the level of the acinar epithelial layer and its expression decreased in cancers with a Gleason score 6 or higher. Our previous studies indicate that increased expression of AT2R alone induced apoptosis in the prostate cancer lines via an extrinsic cell death signaling pathway that is dependent on activation of p38 mitogen-activated protein kinase, caspase-8, and caspase-3, an effect that did not require Ang II.
In this study, we explored the AT2R overexpression mediated effects on prostate cancer cell proliferation, apoptosis and tumor growth in vivo. The human prostate cancer DU145 cells were implanted into the left armpit of nude mice subcutaneously to get the xenograft tumor model of prostate cancer. Three weeks later, mice bearing a tumor (about 0.5cm) were chosen, divided into three groups in random: AT2R group, GFP group, PBS group, and directly injected into xenograft tumor in every three days with recombinant adenoviruses encoding AT2R(Ad5-CMV-AT2R-EGFP) , EGFP(Ad5-CMV-EGFP) and PBS (Ad5-AT2R and Ad5-EGFP. The tumor sizes of the tumor bearing mice were mearsured. The xenograft tumors were made in frozen sections and slices were treated according to instruction of TUNEL test kit and immunohistochemical staining for Ki67. The results demostrated that tumor of the Ad-AT2R group was signifi cantly smaller than Ad-GFP group and PBS group (P<0.05). In the immunohistochemical staining, the positive expression of Ki67 in AT2R group was lower than in GFP group and PBS group (P<0.01). The TUNEL analysis showed an increased number of TUNEL-positive cell in the AT2R group compared with GFP group and PBS group (P<0.01).
In summary, AT2R overexpression induced apoptosis in the prostate cancer cells and inhibited prostate cancer cell proliferation in xenograft tumor growth in vivo, AT2R is becoming a promising target gene for prostate cancer gene therapy.
